- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03876470
Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia (CHIME)
April 15, 2019 updated by: Rebecca Dillingham, MD/MPH, University of Virginia
Micro-elimination of Hepatitis C in a Rural Appalachian Community: The Implementation and Expansion of an Innovative Collaborative Care Model of Telehealth and Knowledge Sharing Focusing on People Who Inject Drugs
The objective of this protocol is to conduct a comprehensive quantitative and qualitative assessment of the impact of our innovative collaborative telehealth HCV care model on patient treatment experiences and quality of life.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The investigators will evaluate the proportion of patients at each step of the HCV care cascade before and after implementation of the collaborative care model.
Additionally, participants will complete questionnaires at three time points: at the initiation of hepatitis C treatment, at treatment completion, and at the assessment of sustained virologic response.
Questionnaires will assess quality of life, mental health, chronic liver disease outcomes, and substance use.
A subset of participants will also complete semi-structured interviews at each of the three time points.
Then, a smaller subset of participants will be selected for a detailed ethnographic case study focusing on treatment experiences, quality of life, forms of social support, and illness experience.
Study Type
Observational
Enrollment (Anticipated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rebecca Dillingham, MD
- Phone Number: 4349820103
- Email: RD8V@hscmail.mcc.virginia.edu
Study Contact Backup
- Name: Chelsea Canan, PhD
- Phone Number: 4349241987
- Email: CC4WD@hscmail.mcc.virginia.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
A total of 300 subjects will be enrolled.
Of these, 20 will be enrolled in the qualitative interviews and 4 will be enrolled in the ethnographic case studies.
Description
Inclusion Criteria:
- 18 years or older
- Detectable HCV viral load
- Attended a clinic appointment at one of our participating sites
Exclusion Criteria:
- Cognitive disability such that informed consent cannot be obtained
- Prisoners
- Unable to understand English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All Participants
All participants will receive HCV treatment as determined by their provider.
HCV treatment is not assigned by the study.
|
Participants' providers will determine the type of HCV treatment as appropriate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort-level Hepatitis C Treatment Progress
Time Frame: 12 months
|
Change in the proportion of patients at each step of the HCV care continuum (linkage to care, treatment initiation, treatment completion and sustained virologic suppression) before and after program implemenation
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Quality-of-Life
Time Frame: 12 months
|
Change in SF-12 scores from treatment initiation to treatment completion and sustained virologic response
|
12 months
|
Depression
Time Frame: 12 months
|
Change in Patient Health Questionnaire-2 (PHQ-2) scores from treatment initiation to treatment completion and sustained virologic response.
Scale range: 0 to 6 with a higher score indicative of greater depressive symptoms.
|
12 months
|
Health-Related Quality-of-Life
Time Frame: 12 months
|
Change in Chronic Liver Disease Questionnaire: Hepatitis C version (CLDQ-HCV) scores from treatment initiation to treatment completion and sustained virologic response.
Scores range from 1 to 7 with higher scores indicative of better quality of life.
CLDQ-HCV includes a total score and 4 sub-scales (activity/energy, emotional, worry, and systemic), each scored from 1 to 7.
|
12 months
|
Semi-Structured Qualitative Interview about Impact of HCV Treatment
Time Frame: 12 months
|
Qualitative assessment of participants' experience with HCV treatment, including its impact on substance use behaviors, activities of daily living, social interactions, and mental and physical health
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rebecca Dillingham, MD, University of Virginia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 15, 2019
Primary Completion (Anticipated)
November 1, 2020
Study Completion (Anticipated)
November 30, 2020
Study Registration Dates
First Submitted
February 25, 2019
First Submitted That Met QC Criteria
March 12, 2019
First Posted (Actual)
March 15, 2019
Study Record Updates
Last Update Posted (Actual)
April 17, 2019
Last Update Submitted That Met QC Criteria
April 15, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21167
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Sohag UniversityRecruiting
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
Clinical Trials on Hepatitis C treatment as chosen by provider
-
BayerAmgenWithdrawnCarcinoma, HepatocellularUnited States
-
University of California, San DiegoTerminated
-
Macfarlane Burnet Institute for Medical Research...St Vincent's Hospital MelbourneCompletedHepatitis CAustralia, New Zealand
-
US Department of Veterans AffairsUniversity of Maryland, Baltimore CountyCompletedSchizophrenia | Schizoaffective Disorder | Major DepressionUnited States
-
Cool Aid Community Health CentreCompleted
-
Hôpital le VinatierRecruiting
-
PfizerCompleted
-
Laval UniversityCanadian Institutes of Health Research (CIHR); Estrie University Integrated... and other collaboratorsCompleted
-
University of Texas at AustinActive, not recruitingHepatitis C Virus InfectionUnited States
-
Klinikum der Universitaet Muenchen, GrosshadernCompleted